This newly isolated cannabinoid, named Cannabizetol (CBGD), is a dimeric cannabinoid. This important discovery is expected to expand knowledge about the therapeutic and medicinal potential of the cannabis plant.

In a new paper, the researchers explained that, in addition to its exciting medical discovery, Cannabizetol is formed by two cannabinoid molecules linked by a methylene bridge, making it the third member of the rare class of dimeric cannabinoids and one of only four dimeric molecules currently identified in cannabis. The study states: "We demonstrated that Cannabizetol exhibits significant antioxidant and skin anti-inflammatory activity, markedly higher than that of the known dimeric cannabinoid Cannabitwinol (CBDD). These results highlight Cannabizetol as a highly promising bioactive metabolite with great potential for dermatological applications."

Authors from Italy and Switzerland wrote in the September 2025 issue of the peer-reviewed Journal of Natural Products that their findings "suggest that among the many still poorly understood cannabinoids, other methylene-bridged dimers of cannabinoids exist, including dimers composed of two different cannabinoids, with astonishing potential bioactivity." The study authors wrote: "The compound was isolated and identified from cannabis extracts, and its existence was confirmed through a chemically synthesized standard that perfectly matched the natural isolate. The availability of a chemically synthesized standard is crucial for unambiguous identification, thereby confirming the natural occurrence of this new cannabis compound. Natural dimeric compounds are of considerable significance because they enable further exploration of chemical space, potentially yielding novel bioactivities beyond those of their respective monomers."

The researchers used multiple inflammatory genes to test the anti-inflammatory activity of Cannabizetol. After 6 hours of treatment, they reported that "the anti-inflammatory activity of these molecules on 84 inflammatory genes was evaluated using an RT-PCR array (RT² Profiler PCR Array, Human Inflammatory Cytokines & Receptors, QIAGEN Srl, Hilden, Germany), achieving the aforementioned effects." In keratinocyte experiments, Cannabizetol demonstrated concentration-dependent inhibition of inflammatory markers such as NF-κB activation and IL-8 release, achieving complete inhibition at relatively low doses, indicating significant potential for suppressing inflammation. NF-κB is a molecular pathway that acts like a master switch for inflammation due to its broad effects on various cells involved in inflammatory processes.

This research comes at a time when detection equipment is becoming increasingly sophisticated, allowing scientists to delve deeper into the growing variety of cannabinoids. Over 150 cannabinoids are currently known, but many still require further study to determine their properties. The authors emphasized that to enhance availability for further research, the researchers developed optimized synthetic pathways, including continuous flow chemistry techniques, which significantly shorten reaction times compared to traditional batch methods. Although yields remain low, this process provides a reliable source of the compound for ongoing studies.

This study builds on previous research and is groundbreaking. It is well known that the primary intoxicating compound in the cannabis plant, tetrahydrocannabinol (THC), was isolated and discovered by renowned Israeli scientists in 1964. It wasn't until the 1990s that the endocannabinoid system was discovered in rats and humans. Building on this, scientists have isolated other compounds with potential therapeutic effects, including cannabidiol, cannabigerol, cannabichromene, and cannabinol, among others. Concurrently, a series of new studies on cannabinoids are underway.

In May of this year, scientists reported the discovery of 33 "significant markers" in the cannabis genome that "significantly influence cannabinoid production," a finding expected to rapidly advance the development of new plant varieties with specific cannabinoid profiles. Furthermore, in April, researchers successfully identified a novel cannabinoid produced by the cannabis plant—cannabielsoxa—along with several other compounds "reported for the first time from Sativa cannabis flowers." Additionally, a South Korean government and university research team evaluated the anti-tumor effects of 11 compounds from cannabis on neuroblastoma cells, finding that seven of them "exhibited potent inhibitory activity."

Finally, the research team noted that the discovery of Cannabizetol underscores that there are still many unknowns within the "cannabinome." Although Cannabizetol is very scarce, constituting less than 0.1% of the natural cannabis plant, its highly promising anti-inflammatory activity may open new avenues for skin health treatments. This not only adds a new cannabinoid to the scientific record but also highlights the potential for novel therapeutic applications hidden within lesser-known cannabis compounds.

END